"10.1371_journal.pone.0016377","plos one","2011-02-16T00:00:00Z","Lixin Wang; Mulugeta Million; Jean Rivier; Catherine Rivier; Noah Craft; Mary P Stenzel-Poore; Yvette Tach√©","Division of Digestive Diseases, Department of Medicine, CURE and Center for Neurobiological Stress, David Geffen School of Medicine at University of California Los Angeles, VA Greater Los Angeles Healthcare System, Los Angeles, California, United States of America; Clayton Foundation Laboratories for Peptide Biology, Salk Institute for Biological Studies, San Diego, California, United States of America; Divisions of Dermatology and Infectious Diseases, Department of Medicine, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, David Geffen School of Medicine at University of California Los Angeles, Torrance, California, United States of America; Department of Molecular Microbiology and Immunology, Oregon Health & Sciences University, Portland, Oregon, United States of America","Conceived and designed the experiments: MM LW YT JR NC. Performed the experiments: LW MM. Analyzed the data: MM LW CR NC. Contributed reagents/materials/analysis tools: YT JR CR MPS-P. Wrote the paper: LW MM YT JR NC. Synthetized the peptide and participated in the design of experiment: JR. Designed and generated mice and worked on manuscript: MPS-P.","The authors have read the journals policy and have the following conflict: JR is Founder, equity owner, President, and Chair of scientific advisory board of Sentia Medical Sciences, Inc. Sentia has an exclusive license from the Salk Institute for astressin B and analogs (US patent numbers 6,323,312, 5,874,227, 5,777,073 and 7,141,546). This does not alter the authors adherence to all the PLoS ONE policies on sharing data and materials.","2011","02","Lixin Wang","LW",7,TRUE,5,2,4,5,TRUE,TRUE,FALSE,0,NA,FALSE
